RTW Investments LP Sells 3,853,879 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

RTW Investments LP decreased its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 20.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,946,420 shares of the company's stock after selling 3,853,879 shares during the quarter. RTW Investments LP owned approximately 7.29% of Taysha Gene Therapies worth $30,042,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Creative Planning acquired a new stake in shares of Taysha Gene Therapies during the third quarter valued at about $28,000. China Universal Asset Management Co. Ltd. raised its holdings in Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock valued at $79,000 after buying an additional 17,446 shares during the last quarter. Privium Fund Management B.V. boosted its position in Taysha Gene Therapies by 21.8% during the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company's stock worth $241,000 after buying an additional 21,500 shares during the period. Principal Financial Group Inc. bought a new stake in Taysha Gene Therapies during the 2nd quarter worth approximately $48,000. Finally, Quantum Private Wealth LLC increased its position in Taysha Gene Therapies by 4.6% in the 2nd quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company's stock valued at $1,636,000 after acquiring an additional 32,000 shares during the period. Institutional investors and hedge funds own 77.70% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group upped their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Chardan Capital restated a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $6.63.

Taysha Gene Therapies Stock Down 3.1 %

NASDAQ TSHA traded down $0.08 on Thursday, hitting $2.38. 5,411,084 shares of the company were exchanged, compared to its average volume of 2,838,417. Taysha Gene Therapies, Inc. has a 12 month low of $1.19 and a 12 month high of $4.32. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The company has a market cap of $487.76 million, a PE ratio of 3.78 and a beta of 0.79. The stock has a fifty day moving average of $2.10 and a 200-day moving average of $2.38.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.